When does Wegovy work — and what does progress actually feel like?

You've just done your first injection. What happens now?

Picture it: the pen goes back in the fridge door, next to the milk, and you're not entirely sure what you're waiting for. That first week at 0.25mg is a tolerability phase. The dose at this stage is low by design, semaglutide needs time to settle into your system, and starting gently reduces the nausea and digestive discomfort that can otherwise make the early weeks miserable.

For most people, that first fortnight feels subtle. Some notice a slight reduction in appetite, a small shift in the urgency of hunger, or that they feel full rather sooner than usual at mealtimes. Others notice very little at first, and that's equally normal. The mechanism (semaglutide acting on GLP-1 receptors in the brain and gut to slow gastric emptying and signal fullness) is described clearly in the NHS medicines page for semaglutide. If you're curious about when Wegovy starts to work and what the early timeline looks like, that page sets out what to expect week by week. The 0.25mg starting dose isn't designed to drive weight loss directly; it's there to help your body adjust.

If GI symptoms do appear, they're usually mild and short-lived. Nausea is the most commonly reported one, tending to peak in the days following each injection and easing as the week goes on. For more on how Wegovy works at a biological level, that detail is worth reading before your first dose.

Weeks four to sixteen: the titration window when appetite really shifts

By the time you reach your second dose level (0.5mg at around week five, then 1.0mg, then 1.7mg), most people report a noticeably different relationship with food. Hunger is less insistent. Cravings that used to be hard to ignore simply don't arrive with the same force. This is where the majority of patients start to see the scales move consistently.

Weight loss during titration is typically steady rather than dramatic. A rate of around 0.5–1kg per week is common during this phase, though it varies depending on starting weight, diet, activity levels and individual response to the medicine. Some people lose more; some lose less. The question of whether Wegovy takes time to work gets asked a lot, and the answer is yes, deliberately so, because the titration schedule exists to balance effectiveness with tolerability.

This period is also when it's worth being honest with yourself about what's changed in your eating patterns. Wegovy reduces appetite; it doesn't remove the need to respond to that reduced appetite by eating well. Protein intake and hydration matter especially during active weight loss, and those questions are worth raising with your prescriber or a dietitian.

Six months in: what the evidence says about where results tend to land

The STEP 1 trial, published in the New England Journal of Medicine, followed adults receiving semaglutide 2.4mg weekly over 68 weeks alongside lifestyle support. Average weight reduction across the treatment group was around 15% of starting body weight. That's an average (individuals fell both above and below it) but it gives a credible picture of where sustained treatment tends to lead.

For patients eligible for the newer 7.2mg maintenance dose (approved by the MHRA for adults with a BMI of 30 or above), trial data reported average weight loss of around 20.7% over 72 weeks, bringing results closer to those seen with tirzepatide. The full Wegovy overview covers both dose pathways in more detail.

One thing the evidence is clear on: stopping treatment early significantly reduces outcomes. Weight often returns when the medicine is discontinued, which is why NICE guidance and prescribers both emphasise the importance of treating this as a long-term intervention rather than a short course. If you're wondering how results compare across different medicines, the semaglutide page sits that in broader context.

Plateaus, slow weeks and what they actually mean

At some point, most people hit a spell where the number on the scales stops moving. This is not failure. It is physiology. The body adjusts its energy expenditure as weight falls, which is one reason why the path from starting weight to goal weight is rarely a straight line.

Plateaus are especially common around dose transitions, during periods of stress or illness, and at later stages of treatment when the body has already adapted significantly. They're worth mentioning to your prescriber, not because something has necessarily gone wrong, but because a clinical review can check whether there's anything adjustable, timing, lifestyle factors, whether the current dose is the right one for you.

Cost is sometimes a factor in whether people continue or pause treatment. Wegovy pricing in the UK is worth understanding clearly before you start, so there are no surprises. Equally, a break from treatment taken without clinical guidance often undoes progress faster than people expect, so if cost is the concern, that's a conversation worth having before stopping.

If you'd like to talk through where you are in treatment or whether Wegovy is the right starting point, speaking to our prescribers costs nothing and takes no commitment. A real clinician reads every consultation the same day.